3500万美元到账后,宜明昂科超20亿美元BD合作终止,创始人田文志:美国临床推进缓慢

时代财经
Jan 07

宜明昂科为何与美国药企终止协议?图片来源:图虫创意一笔超20亿美元的BD交易在管线推进至半路时被叫停,市场对此产生诸多疑问。1月6日晚间,港股上市公司宜明昂科(01541.HK)对外宣布,其与Instil Bio(TIL.US)子公司Axion Bio终止了关于新型PD-L1xVEGF双特异性抗体IMM2510/AXN-2510和新一代CTLA-4抗体IMM27M/AXN-27M的许可与合作协议。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10